GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.
| Website | http://www.gentibio.com |
| Employees | 43 (40 on RocketReach) |
| Founded | 2020 |
| Address | 150 Cambridgepark Dr Floor 9, Cambridge, Massachusetts 02140, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+11 more
(view full list)
|
| Industry | Biotechnology, Drug Discovery |
| Keywords | Immunotherapy, Immune Cell Therapy, Biotherapeutics, Cell Therapy, Immune Modulation, Targeted Therapy, Biologics, Precision Medicine, Regenerative Medicine, Drug Development, Clinical Trials |
| Competitors | 克睿基因 Cure Genetics, CureVac, Geno, Sangamo Therapeutics, Inc., Moderna Therapeutics, Celyad Oncology, Curexa Pharmacy, Zymeworks Inc., Zymergen, Inc., AbCellera +44 more (view full list) |
Looking for a particular GentiBio employee's phone or email?
Andy Walker is the Co-founder, President and Chief Executive Officer (CEO) of GentiBio.
40 people are employed at GentiBio.
GentiBio is based in Cambridge, Massachusetts.